Table 1 Demographics and clinical data.

From: Immune marker levels in severe mental disorders: associations with polygenic risk scores of related mental phenotypes and psoriasis

 

SCZ, N = 595

BD, N = 409

HC, N = 947

SMD vs HCa

Subgroup comparisonsb

Sex female, N (%)

253 (42.5)

240 (58.7)

436 (46.0)

ns

HC, BD > SCZ

Age, mean (SD)

31.6 (10.1)

35.0 (12.4)

34.0 (9.3)

0.04

HC, BD > SCZ

GAF-symptoms, mean (SD)

45 (12)

58 (12)

 

n/a

BD > SCZ

GAF-function, mean (SD)

46 (13)

56 (13)

 

n/a

BD > SCZ

Medication, N (%)

 Antipsychotics

494 (83.0)

200 (48.9)

 

n/a

SCZ > BD

 Anticonvulsants

82 (13.8)

147 (35.9)

 

n/a

BD > SCZ

 Lithium

15 (2.5)

69 (16.9)

 

n/a

BD > SCZ

 Antidepressants

170 (28.6)

147 (35.9)

 

n/a

BD > SCZ

Diagnose, N (%)

 Schizophrenia

339 (57.0)

  

n/a

n/a

 Schizophreniform

36 (6.1)

  

n/a

n/a

 Schizoaffective

85 (14.3)

  

n/a

n/a

 Bipolar disorder 1

 

229 (56.0)

 

n/a

n/a

 Bipolar disorder 2

 

123 (30.1)

 

n/a

n/a

 Bipolar disorder NOS

 

19 (4.6)

 

n/a

n/a

 Major depressive disorder

 

38 (9.3)

 

n/a

n/a

 Psychosis NOS

82 (13.8)

  

n/a

n/a

 Brief psychotic disorder

14 (2.4)

  

n/a

n/a

 Delusional disorder

39 (6.6)

  

n/a

n/a

  1. BD bipolar spectrum disorders, GAF general assessment of functioning scale, ns not significant, n/a not applicable, SCZ schizophrenia spectrum disorders, SMD severe mental disorders.
  2. aP value of SMD versus HC: chi square for categorical variables, t test for continuous variables, bchi square for categorical variables, ANOVA for continuous variables.
Back to article page